Etilevodopa
![]() | |
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate | |
| Identifiers | |
| CAS Number |
37178-37-3 |
| ATC code | N04BA06 (WHO) (combination with decarboxylase inhibitor) |
| PubChem | CID 170345 |
| ChemSpider |
148944 |
| UNII |
895X917GYE |
| KEGG |
D04097 |
| Chemical data | |
| Formula | C11H15NO4 |
| Molar mass | 225.241 g/mol |
| |
| |
| (verify) | |
Etilevodopa (TV-1203) is a dopaminergic agent which was developed as a treatment for Parkinson's disease.[1] It is the ethyl ester of levodopa. It was never marketed.
See also
References
- ↑ Djaldetti Ruth, Giladi Nir, Hassin-Baer Sharon, Shabtai Hertzel, Melamed Eldad (November–December 2003). "Pharmacokinetics of Etilevodopa Compared to Levodopa in Patient's With Parkinson's Disease: An Open-label, Randomized, Crossover Study". Clinical Neuropharmacology 26 (6): 322–326. doi:10.1097/00002826-200311000-00012.
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

